Nykode Therapeutics ASA

As of June 30, 2026, Nykode Therapeutics ASA carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 626.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nykode Therapeutics ASA's next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, Nykode Therapeutics ASA has 326.55M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nykode Therapeutics ASA maintains a current ratio of 11.52, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.22, indicating elevated leverage, while an interest coverage ratio of -250.25 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA posted a negative return on equity (ROE) of -25.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA recorded an income tax benefit of -13.21M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -240.26M and -227.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Nykode Therapeutics ASA's stock has gained approximately 39.54% over the past 52 weeks. The 50-day moving average sits at 3.82, while the 200-day moving average is 3.30.

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA generated - - in revenue and converted that into -227.05M in net income, yielding earnings per share of -0.59. EBITDA reached -252.47M, while operating income came in at -273.47M.

As of June 30, 2026, Nykode Therapeutics ASA holds 443.03M in cash and equivalents against 17.66M in total debt, resulting in a net debt position of -443.03M. Total book value stands at 795.09M, with working capital of 435.27M providing operational flexibility.

Nykode Therapeutics ASA produced -268.45M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9,891.00 in capital expenditures, free cash flow totaled -268.46M - equivalent to -0.70 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -21.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nykode Therapeutics ASA shareholders.

Nykode Therapeutics ASA's most recent stock split took place on July 7, 2020 with a 1:5 split ratio.

As of June 30, 2026, Nykode Therapeutics ASA has an Altman Z-Score of 10.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.